Tenax Therapeutics, Inc. (TENX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Chapel Hill, NC, 美国. 现任CEO为 Christopher T. Giordano.
TENX 拥有 IPO日期为 1994-04-04, 4 名全职员工, 在 NASDAQ Capital Marke, 市值为 $240.94M.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
